Abstract:Background: Few biological or clinical predictors guide medication selection and/or dosing for attention-deficit/hyperactivity disorder (ADHD). Accumulating data suggest that genetic factors may contribute to clinically relevant pharmacodynamic (e.g., dopamine transporter-SLC6A3 also commonly known as DAT1) or pharmacokinetic (e.g., the drug metabolizing enzyme Cytochrome P450 2D6 CYP2D6) effects of methylphenidate (stimulant) and atomoxetine (non-stimulant), which are commonly prescribed medications. This is the first study of youth with ADHD exposed to both medications examining the clinical relevance of genetic variation on treatment response. Methods: Genetic variations in DAT1 and CYP2D6 were examined to determine how they modified time relationships with changes in ADHD symptoms over a 4-week period in 199 youth participating in a double-blind crossover study following a stepped titration dose optimization protocol. Results: Our results identified trends in the modification effect from CYP2D6 phenotype and the time-response relationship between ADHD total symptoms for both medications (atomoxetine [ATX]: p = 0.058, Methylphenidate [MPH]: p = 0.044). There was also a trend for the DAT1 3' untranslated region (UTR) variable number of tandem repeat (VNTR) genotype to modify dose relationships with ADHD-RS total scores for atomoxetine (p = 0.029). Participants with DAT1 9/10 repeat genotypes had a more rapid dose-response to ATX compared to 10/10, while those with 9/9 genotypes did not respond as doses were increased. Regardless of genotype, ADHD symptoms and doses were similar across CYP2D6 metabolizer groups after 4 weeks of treatment. Conclusions: Most children with ADHD who were CYP2D6 normal metabolizers or had DAT1 10/10 or 9/10 genotypes responded well to both medications. While we observed some statistically significant effects of CYP2D6 and DAT1 with treatment response over time, our data indicate that genotyping for clinical purposes may have limited utility to guide treatment decisions for ATX or MPH because both medications were generally effective in the studied cohort after 3 weeks of titration to higher doses. The potential DAT1 association with ATX treatment is a novel finding, consistent with prior reports suggesting an association of the DAT1 in 9/9 genotypes with lower responsive rates to treatment at low and moderate doses.

The Association with Quantitative Response to Attention-Deficit/Hyperactivity Disorder Medication of the Previously Identified Neurodevelopmental Network Genes.

Dopamine Transporter and CYP2D6 Gene Relationships with Attention-Deficit/Hyperactivity Disorder Treatment Response in the Methylphenidate and Atomoxetine Crossover Study

Association of better atomoxetine response with polymorphisms of CYP2D6 gene in the treatment of attention-deficit/hyperactivity disorder

Evaluation of potential gene-gene interactions for attention deficit hyperactivity disorder in the Han Chinese population.

Mendelian Randomization Analysis of the Brain, Cerebrospinal Fl Uid, and Plasma Proteome Identi Fi Es Potential Drug Targets for Attention De Fi Cit Hyperactivity Disorder

Advances in Molecular Genetic Studies of Attention Deficit Hyperactivity Disorder in China.

Adrenergic Neurotransmitter System Transporter and Receptor Genes Associated with Atomoxetine Response in Attention-Deficit Hyperactivity Disorder Children

A High-Density Single-Nucleotide Polymorphism Screen of 23 Candidate Genes in Attention Deficit Hyperactivity Disorder: Suggesting Multiple Susceptibility Genes among Chinese Han Population

Variants of Dopamine Beta Hydroxylase Gene Moderate Atomoxetine Response in Children with Attention-Deficit/Hyperactivity Disorder

Shared and Unique Effects of Long-Term Administration of Methylphenidate and Atomoxetine on Degree Centrality in Medication-Naïve Children with Attention-Deficit/Hyperactive Disorder

Association of Norepinephrine Transporter Gene with Methylphenidate Response.

Pharmacogenetics of Methylphenidate Response in Preschoolers with ADHD

No Significant Association between the Alpha-2A-Adrenergic Receptor Gene and Treatment Response in Combined or Inattentive Subtypes of Attention-Deficit Hyperactivity Disorder

[Association of 14 Polymorphisms in the Five Candidate Genes and Attention Deficit Hyperactivity Disorder].

The study of the association between COMT polymorphisms and methylphenidate response in the treat-ment of attention deficit hyperactivity disorder

Polygenic risk of genes involved in the catecholamine and serotonin pathways for ADHD in children

DAT1methylation is Associated with Methylphenidate Response on Oppositional and Hyperactive-Impulsive Symptoms in Children and Adolescents with ADHD

Interactions Between MAOA and SYP Polymorphisms Were Associated with Symptoms of Attention—deficit/hyperactivity Disorder in Chinese Han Subjects

Advances in molecular geneitc studies of atteniton deifcit hyperacitvity disorder in China

Genetic evidence for the association of the hypothalamic-pituitary-adrenal (HPA) axis with ADHD and methylphenidate treatment response

Polygenic Transmission And Complex Neuro Developmental Network For Attention Deficit Hyperactivity Disorder: Genome-Wide Association Study Of Both Common And Rare Variants